ArticlePharmaceutical research2010
Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations.
Article in Pharmaceutical research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Enabling global access to potent subunit vaccines with a simple and scalable injectable hydrogel platform.Biomaterials science · 2026Article
- Non-Invasive Vaccines: Challenges in Formulation and Vaccine Adjuvants.Pharmaceutics · 2023Review
- Progress in microneedle array patch (MAP) for vaccine delivery.Human vaccines & immunotherapeutics · 2021Article
- Needle-Free Immunization with Chitosan-Based Systems.International journal of molecular sciences · 2018Review
- Coated and Hollow Microneedle-Mediated Intradermal Immunization in Mice with Diphtheria Toxoid Loaded Mesoporous Silica Nanoparticles.Pharmaceutical research · 2018Article
- Novel application of trimethyl chitosan as an adjuvant in vaccine delivery.International journal of nanomedicine · 2018Review
- Nanoporous Microneedle Arrays Effectively Induce Antibody Responses against Diphtheria and Tetanus Toxoid.Frontiers in immunology · 2017Article
- The success of microneedle-mediated vaccine delivery into skin.Human vaccines & immunotherapeutics · 2016Review
- Microneedle patches for vaccination in developing countries.Journal of controlled release : official journal of the Controlled Release Society · 2016Review
- Multifunctional particle-constituted microneedle arrays as cutaneous or mucosal vaccine adjuvant-delivery systems.Human vaccines & immunotherapeutics · 2016Review
- Microneedle patches for vaccine delivery.Clinical and experimental vaccine research · 2014Review
- Microneedles for intradermal and transdermal drug delivery.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2013Review
- Measles vaccination using a microneedle patch.Vaccine · 2013Article
- Microneedles for drug and vaccine delivery.Advanced drug delivery reviews · 2012Review
- Effect of microneedle treatment on the skin permeation of a nanoencapsulated dye.The Journal of pharmacy and pharmacology · 2012Article
- Microneedle-mediated transcutaneous immunization with plasmid DNA coated on cationic PLGA nanoparticles.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- Permeation of antigen protein-conjugated nanoparticles and live bacteria through microneedle-treated mouse skin.International journal of nanomedicine · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to gain insight into the delivery and immunogenicity of N-trimethyl chitosan (TMC) adjuvanted diphtheria toxoid (DT) formulations applied transcutaneously with microneedles.
methodsMice were vaccinated with DT-loaded TMC nanoparticles, a solution of TMC and DT (TMC/DT) or DT alone. The formulations were applied onto the skin before or after microneedle treatment with two different 300-microm-long microneedle arrays and also injected intradermally (ID). As a positive control, alum-adjuvanted DT (DT-alum) was injected subcutaneously (SC). Ex vivo confocal microscopy studies were performed with rhodamine-labelled TMC.
resultsIndependent of the microneedle array used and the sequence of microneedle treatment and vaccine application, transcutaneous immunisation with the TMC/DT mixture elicited 8-fold higher IgG titres compared to the TMC nanoparticles or DT solution. The toxin-neutralising antibody titres from this group were similar to those elicited by SC DT-alum. After ID immunisation, both TMC-containing formulations induced enhanced titres compared to a DT solution. Confocal microscopy studies revealed that transport of the TMC nanoparticles across the microneedle conduits was limited compared to a TMC solution.
conclusionsIn conclusion, TMC has an adjuvant function in transcutaneous immunisation with microneedles, but only if applied in a solution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.